KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Short-term Investments (2016 - 2025)

Historic Short-term Investments for Ionis Pharmaceuticals (IONS) over the last 17 years, with Q3 2025 value amounting to $1.9 billion.

  • Ionis Pharmaceuticals' Short-term Investments fell 1148.81% to $1.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 billion, marking a year-over-year decrease of 1148.81%. This contributed to the annual value of $2.1 billion for FY2024, which is 640.0% up from last year.
  • Per Ionis Pharmaceuticals' latest filing, its Short-term Investments stood at $1.9 billion for Q3 2025, which was down 1148.81% from $2.0 billion recorded in Q2 2025.
  • Ionis Pharmaceuticals' Short-term Investments' 5-year high stood at $2.1 billion during Q3 2024, with a 5-year trough of $1.2 billion in Q4 2021.
  • For the 5-year period, Ionis Pharmaceuticals' Short-term Investments averaged around $1.8 billion, with its median value being $1.9 billion (2024).
  • Its Short-term Investments has fluctuated over the past 5 years, first crashed by 2592.62% in 2021, then skyrocketed by 3729.5% in 2022.
  • Ionis Pharmaceuticals' Short-term Investments (Quarter) stood at $1.2 billion in 2021, then skyrocketed by 37.3% to $1.7 billion in 2022, then increased by 12.95% to $1.9 billion in 2023, then rose by 6.4% to $2.1 billion in 2024, then dropped by 7.48% to $1.9 billion in 2025.
  • Its Short-term Investments was $1.9 billion in Q3 2025, compared to $2.0 billion in Q2 2025 and $1.9 billion in Q1 2025.